<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed a phase I/II study of recombinant human interleukin-3 (rhIL-3) in 21 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received 21-day cycles of IL-3 (0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d) by subcutaneous injection followed by a 10- to 14-day washout period </plain></SENT>
<SENT sid="2" pm="."><plain>Nineteen patients completed at least one 21-day cycle of IL-3 </plain></SENT>
<SENT sid="3" pm="."><plain>Frequent toxicities of IL-3 included <z:hpo ids='HP_0002315'>headache</z:hpo>, <z:hpo ids='HP_0011134'>low-grade fever</z:hpo>, and <z:hpo ids='HP_0010783'>erythema</z:hpo> at the injection site; at higher doses, <z:mp ids='MP_0005456'>weight gain</z:mp> and peripheral <z:hpo ids='HP_0000969'>edema</z:hpo> was seen </plain></SENT>
<SENT sid="4" pm="."><plain>Eleven patients developed <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 20 evaluable patients, eight had increases in absolute neutrophil counts (seven with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, one with AA) including six of the nine patients receiving &gt; or = 5.0 micrograms/kg/d </plain></SENT>
<SENT sid="6" pm="."><plain>One AA patient became transfusion-independent for 8 months, while another AA patient had decreased transfusion requirements </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> had at least a doubling of their platelet count, and another patient experienced a 1.9-fold increase </plain></SENT>
<SENT sid="8" pm="."><plain>One patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> progressed to aleukemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> by the end of one treatment cycle </plain></SENT>
<SENT sid="9" pm="."><plain>IL-3 was well-tolerated, but multilineage effects were seen in only 25% of patients with primary <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> states (five of 20 evaluable) and more commonly in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Its optimal use may be as part of combination hematopoietic growth factor therapy </plain></SENT>
</text></document>